Physician profile
Hal Sreden
NPI 1467555789
$5,306.32
in general payments reported to CMS, 2019-2025
31 companies · $1,091 in 2025
The $1,091 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $767 · 2020: $947 · 2021: $386 · 2022: $333 · 2023: $502 · 2024: $1,280 · 2025: $1,091.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,136 · Travel and Lodging: $652 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,136.24 |
| Travel and Lodging | $651.84 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $1,814.78 | 2019-2024 | Single Use Suction Valve (Sterile) |
| Glaxosmithkline, LLC. | $812.41 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Grifols USA, LLC | $438.44 | 2019-2025 | Prolastin-C Liquid |
| Genzyme Corporation | $302.92 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $208.39 | 2020-2025 | Airsupra, Fasenra, Breztri |
| Mallinckrodt Hospital Products INC. | $188.32 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $167.84 | 2020-2025 | Glassia, Aralast |
| Paratek Pharmaceuticals, INC. | $138.63 | 2022-2023 | Nuzyra |
| Actelion Pharmaceuticals US, INC. | $124.20 | 2023 | Opsumit, Uptravi |
| Abbvie INC. | $122.65 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $115.84 | 2021-2025 | Dupixent |
| Insmed, INC. | $90.97 | 2019-2025 | Arikayce, Brinsupri |
| Mylan Specialty L.P. | $76.85 | 2020-2024 | Yupelri |
| La Jolla Pharmaceutical Company | $69.26 | 2021-2024 | Giapreza |
| Merck Sharp & Dohme LLC | $66.14 | 2021-2025 | Zerbaxa |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $65.22 | 2024-2025 | Zemaira |
| Gilead Sciences, INC. | $63.90 | 2021-2022 | |
| Baxter Healthcare | $52.45 | 2023-2025 | Hillrom - Vest System Model 105 Home Care |
| Philips North America LLC | $52.41 | 2020-2025 | Vest Therapy Und |
| Electromed, INC. | $45.08 | 2025 | Smartvest |
| Verona Pharma, INC. | $44.70 | 2025 | Ohtuvayre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.84 | 2019-2025 | Ofev |
| Ethicon INC. | $39.18 | 2024 | Monarch Platform |
| United Therapeutics Corporation | $35.83 | 2024 | Tyvaso |
| Masimo Corporation | $25.80 | 2024 | |
| Viatris Specialty LLC | $23.88 | 2025 | Yupelri |
| Novartis Pharmaceuticals Corporation | $18.98 | 2025 | |
| Allergan, INC. | $18.13 | 2020 | |
| Sunovion Pharmaceuticals INC. | $17.32 | 2020 | |
| Siemens Medical Solutions USA, INC. | $14.15 | 2024 | Cios Spin |
| Circassia INC. | $10.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hal Sreden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.